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Synopsis 26 
Objectives 27 
Development of antibiotic-resistant strains of coagulase-negative staphylococci has 28 
complicated the management of infections associated with the use of invasive 29 
medical devices, and innovative treatment and prophylactic options are needed. 30 
Honey is increasingly being used to treat infected wounds, but little is known about its 31 
effectiveness against coagulase-negative staphylococci. The aim of this study was to 32 
determine the minimum active dilution of two standardized, representative honeys for 33 
18 clinical isolates of coagulase-negative staphylococci. 34 
Methods 35 
An agar incorporation technique was used to determine the minimum active dilution, 36 
with dilution steps of 1% (v/v) honey (or steps of 5% (v/v) of a sugar syrup matching 37 
the osmotic effect of honey). The plates were inoculated with 10 l spots of cultures 38 
of the isolates.  39 
Results 40 
The honeys were inhibitory at dilutions down to 3.6 (± 0.7) % (v/v) for the pasture 41 
honey, 3.4 (± 0.5) % (v/v) for the manuka honey, and 29.9 (± 1.9) % (v/v) for the 42 
sugar syrup. 43 
Conclusions 44 
Typical honeys are about eight times more potent against coagulase-negative 45 
staphylococci than if bacterial inhibition were due to their osmolarity alone. Therefore 46 
honey applied to skin at the insertion points of medical devices may have a role in 47 
the treatment or prevention of infections by coagulase-negative staphylococci. 48 
Introduction 49 
Until the 1960s coagulase-negative staphylococci were regarded as saprophytic 50 
commensals of low pathogenicity that normally inhabit human skin and mucosal 51 
membranes. However, increased recovery rates from clinical specimens prompted a 52 
re-evaluation of their clinical status to opportunist pathogens and they are now 53 
among the five most frequently isolated causative agents of hospital-acquired 54 
infection,1, 2 often associated with the use of temporary and permanent invasive 55 
medical devices (e.g. intravenous catheters, continuous ambulatory peritoneal 56 
dialysis catheters, urethral stents, endotracheal tubes, cerebrospinal fluid shunt 57 
mechanisms, prosthetic heart valves and orthopaedic prostheses) because of their 58 
ability to adhere to synthetic polymeric biomaterials and form biofilms.1 Although 59 
Staphylococcus epidermidis is the coagulase-negative staphylococcus most 60 
commonly isolated from clinical specimens, other species have also emerged as 61 
opportunist pathogens.2, 3 The emergence of methicillin-resistant coagulase-negative 62 
staphylococci and strains with multiple antibiotic resistance has made this an 63 
increasingly difficult group to treat.2 Management of infections associated with 64 
medical devices usually requires removal of the prosthetic device and the 65 
administration of systemic antibiotics.1, 4 Although all devices are sterilised at the 66 
outset, cross-infection from skin is probably responsible for contamination of devices 67 
during implantation or subsequent use. 68 
The severe consequences to patients with such infections demands effective 69 
strategies designed to minimise and eliminate infections.1, 4 Although use of electric 70 
fields to improve antibiotic therapy, modification of polymeric biomaterial to reduce 71 
bacterial adherence, and incorporation of antimicrobial agents into devices to reduce 72 
bacterial growth have been explored1, a solution has yet to be found. 73 
Honey is increasingly being used in the management of infected wounds where 74 
conventional pharmaceutical products are failing, especially now that CE-marked 75 
sterile honey and honey-impregnated dressings are available,5 thus it is reasonable 76 
to consider prophylactic application of honey in situ at device exit sites.  77 
Although susceptibility to the antibacterial activity of honey of other pathogens is 78 
established in vitro,6-8 coagulase-negative staphylococci have not been tested. This 79 
study was undertaken to determine their susceptibility to honey in vitro. The 80 
antibacterial activity of honey varies not only between floral sources but even within 81 
one floral source,9 so representative honeys with median levels of activity were used. 82 
The antimicrobial activity in most honeys is due to the enzymic production of 83 
hydrogen peroxide, but honey from some Leptospermum species, such as manuka, 84 
can also have a high antimicrobial activity due to an unidentified phytochemical 85 
component:9 both types of activity were studied. Also, to distinguish these activities 86 
from any osmotic inhibition of bacteria, a syrup simulating honey was included in the 87 
study as a control. 88 
Materials and methods 89 
Honey 90 
The two natural honeys used were selected to be close to the median antibacterial 91 
activity for each type of activity, tested against Staphylococcus aureus (ATCC 92 
25923): 10 a manuka honey with non-peroxide activity equivalent to 16.8% (w/v) 93 
phenol and a pasture honey with hydrogen peroxide activity equivalent to 17.5% 94 
(w/v) phenol. The simulated honey was prepared by combining 38.4 g fructose, 30.3 95 
g glucose, 1.3 g sucrose, 8.6 g maltose and 1.4 g maltodextrin with 17.2 mL distilled 96 
water. 97 
Bacterial isolates 98 
Isolates of coagulase-negative staphylococci were obtained from eighteen Waikato 99 
Hospital patients. Cultures were isolated from midstream and catheter urines, 100 
peritoneal fluid, cerebrospinal fluid, breast aspirate, a peritoneal catheter tip and 101 
blood cultures. The isolates were identified using a range of biochemical and 102 
morphological techniques, and the Vitek automated bacterial identification instrument 103 
(McDonnell Douglas Health System Company). 104 
The isolates were stored on Protect Bacterial Preserver Beads (LabSupply Pierce) at 105 
-70°C. We confirmed identity of the isolates to species level by means of BBL Crystal 106 
gram positive kits (Becton Dickinson N.Z.). 107 
Microbiological materials 108 
Trypticase soy broth (TSB) was obtained from Difco Laboratories. Nutrient agar was 109 
obtained from Scharlau Laboratories. Blood agar base was obtained from Merck 110 
Laboratories, and 5% sterile defibrinated sheep’s blood (Life Technologies N.Z.) was 111 
added. 112 
Determination of minimum active dilution 113 
Prior to testing, each isolate was cultured from preserver beads by inoculating two 114 
beads into 9 mL of TSB and incubating for approximately 16 h at 37C. Cultures 115 
obtained were diluted with TSB to obtain 2–3 x 107 cfu/mL, the minimum to produce 116 
confluent growth at inoculation positions. 117 
The minimum active dilution of each honey for each of the clinical isolates was 118 
determined by an agar incorporation technique. Nutrient agar was made up at double 119 
strength, measured out into 25 mL aliquots and autoclaved. To prepare the plates it 120 
was melted and tempered in a 50°C water-bath until poured. Solutions of the two 121 
natural honey samples (at a concentration of 20% v/v) and the simulated honey (at a 122 
concentration of 70% v/v) were prepared in sterile de-ionised water immediately prior 123 
to performing an assay and diluted with different volumes of sterile de-ionised water 124 
to give double the final concentration required in a volume of 25 mL. These solutions 125 
were then also tempered at 50°C then each mixed with one of the 25 mL lots of 126 
double-strength nutrient agar. The various agar-honey mixtures were then poured 127 
into duplicate petri-dishes.  128 
A dilution series with honey concentrations ranging from 1% to 10% (v/v) final honey 129 
concentration, in 1% increments, was used for the susceptibility assays for the 130 
natural honeys, and from 5% to 35% (v/v) final honey concentration, in 5% 131 
increments, for the simulated honey. Duplicate control plates of nutrient agar with no 132 
honey were included in each susceptibility assay to confirm the viability and density 133 
of the cultures. 134 
Samples (10 µl) of each culture were inoculated onto the agar plates in three rows 135 
using an eight-channel auto-pipettor with tips attached to channels # 1, 3 and 5, to 136 
get nine strains inoculated per plate as evenly spaced spots. Duplicate plates were 137 
inoculated and assays were repeated on two subsequent days, with fresh 138 
subcultures each occasion. 139 
The inoculated plates were incubated at 37°C for 16 h, then growth, partial inhibition 140 
or complete inhibition was recorded at each inoculation position. The minimum active 141 
dilution was taken to be the lowest concentration of honey at which bacterial growth 142 
was completely inhibited, and the mean value for the minimum active dilution was 143 
calculated from the six replicates for each isolate. 144 
Analysis of variance was carried out using GenStat (Lawes Agricultural Trust). 145 
Results 146 
In Table 1 it can be seen that the growth of all eighteen coagulase-negative 147 
staphylococcus isolates was inhibited by manuka and pasture honeys at 148 
concentrations of 2.7–5% (v/v). By contrast, simulated honey inhibited the various 149 
isolates at concentrations of 27.5–31.7% (v/v), showing that the antibacterial activity 150 
observed with the natural honeys was 5.5–11.7 times greater than that due to the 151 
osmotic effect of the sugar content of honey. 152 
The mean values for the results in various groupings of the data are shown in Table 153 
2. There was no significant difference between the two types of natural honey for all 154 
eighteen isolates (p=0.44), nor between the antibiotic-resistant and antibiotic-155 
susceptible isolates (p=0.35), nor between any of the species of bacteria (p=0.66). 156 
Discussion 157 
The results of this study clearly show that honey has the potential to be used as an 158 
antibacterial agent to prevent and control infection with coagulase-negative 159 
staphylococci. The lack of significant difference in susceptibility to honey between 160 
any of the isolates tested (p=0.13) indicates that other isolates are likely to be equally 161 
as susceptible. The similarity in susceptibility to honey between antibiotic-resistant 162 
and antibiotic-susceptible strains was also seen with Staphylococcus aureus.7 163 
These findings show that coagulase-negative staphylococci are very similar to S. 164 
aureus6, 7 in their susceptibility to honey of similar antibacterial potency and more 165 
susceptible than Pseudomonas aeruginosa8 and Enterococcus species (VRE and 166 
VSE),7 thus they can be expected to be controlled by honey in vivo since there are 167 
many reports of honey rapidly healing wounds infected with S.aureus and 168 
pseudomonads.5 The results show that honey could be diluted by exudate up to 169 
twenty-fold and still inhibit their growth, thus honey would be suitably active for both 170 
therapeutic and prophylactic application. The Leptospermum honey on sale as 171 
licensed products for wound care in Australia, Europe and New Zealand5 has a 172 
standardised level of antibacterial activity close to that of the honey samples used in 173 
this study, and so the results are relevant to clinical usage. 174 
There are other advantages in applying honey to the traumatised tissue around 175 
medical devices. Its anti-inflammatory activity can be expected to prevent serous 176 
exudates which can provide a medium for bacteria to colonise.11 Also its physical 177 
properties provide moist conditions ideal for healing, it has a stimulatory action on 178 
growth of wound repair tissues, and unlike other antiseptics it has no harmful effects 179 
on tissues, the slow enzymic production of hydrogen peroxide giving about one 180 
thousandth of that in a 3% hydrogen peroxide solution.11 181 
The development of honey in the form of a rubbery gel which can be moulded to 182 
conform to any shape5 will further increase the practicality of use with medical 183 
devices beyond that with the honey-impregnated dressings currently available. It 184 
remains for further clinical evaluation to be tried. 185 
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